Journal of Nephrology & Therapeutics

Bates M

Publications

• Research Article
  Recombinant Tissue Plasminogen Activator is Safe and Effective in Increasing Haemodialysis Catheter Longevity in Paediatric Haemodialysis Patients
  Author(s): Teoh CW, Bates M, Cotter M, Quinlan C, Dolan NM, Riordan M, Waldron M and Awan ATeoh CW, Bates M, Cotter M, Quinlan C, Dolan NM, Riordan M, Waldron M and Awan A
  
  Background: Haemodialysis catheter (HDC) occlusion is a common cause of poor blood flow, inadequate dialysis and HDC loss. From Jan 2009, our unit used infusions of recombinant tissue plasminogen activator (rtPA), Alteplase 0.1-0.2 mg/kg/hour over 1-2 hours for thrombolysis of occluded catheters. Methods: Retrospective review of outcomes of all patients who were treated with rtPA infusion for HDC occlusion in our unit between Jan 2009 to Dec 2012. Twenty patients underwent 5,407 sessions of catheter-directed haemodialysis in our unit (mean age 7.4 years, range 0.3-15.8 years). Results: Ten patients accounted for 339 episodes of rtPA infusions (median 12, range 1-115). Thirty-three radiographic contrast studies were performed – 21 (64%) confirmed presence of thrombus. The immediate success rate, defined as return .. Read More»
  DOI: 10.4172/2161-0959.1000161

  Abstract PDF